Bifogade filer
Kurs
-4,15%
Likviditet
0,15 MSEK
Prenumeration
Kalender
Tid* | ||
2025-02-20 | 08:30 | Bokslutskommuniké 2024 |
2024-11-13 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-10 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2024-05-08 | - | Årsstämma |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-02-21 | - | Bokslutskommuniké 2023 |
2023-12-15 | - | Split GUARD 50:1 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-10 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2023-05-09 | - | Årsstämma |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-02-24 | - | Extra Bolagsstämma 2023 |
2023-02-22 | - | Bokslutskommuniké 2022 |
2022-12-13 | - | Extra Bolagsstämma 2022 |
2022-11-16 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-13 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2022-05-12 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-22 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-11-08 | - | Extra Bolagsstämma 2021 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-14 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2021-05-12 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-24 | - | Bokslutskommuniké 2020 |
2020-11-18 | - | Kvartalsrapport 2020-Q3 |
2020-09-07 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2020-05-14 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-27 | - | Kvartalsrapport 2019-Q3 |
2019-10-23 | - | Extra Bolagsstämma 2019 |
2019-08-27 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-21 | - | Kvartalsrapport 2019-Q1 |
2019-03-20 | - | Bokslutskommuniké 2018 |
2019-01-24 | - | Extra Bolagsstämma 2018 |
2018-11-21 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-06-01 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2018-05-31 | - | Årsstämma |
2018-05-23 | - | Kvartalsrapport 2018-Q1 |
2018-02-23 | - | Bokslutskommuniké 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-05-19 | - | Split GUARD 20:1 |
2017-04-28 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2017-04-27 | - | Årsstämma |
2017-03-14 | - | Extra Bolagsstämma 2017 |
2017-02-22 | - | Bokslutskommuniké 2016 |
2016-11-18 | - | Kvartalsrapport 2016-Q3 |
2016-08-19 | - | Kvartalsrapport 2016-Q2 |
2016-05-03 | - | Extra Bolagsstämma 2016 |
2016-04-28 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2016-04-27 | - | Årsstämma |
2016-04-22 | - | Kvartalsrapport 2016-Q1 |
2016-02-19 | - | Bokslutskommuniké 2015 |
2015-11-02 | - | Extra Bolagsstämma 2015 |
2015-10-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-20 | - | Kvartalsrapport 2015-Q2 |
2015-05-29 | - | Kvartalsrapport 2015-Q1 |
2015-05-18 | - | Årsstämma |
2015-04-29 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2015-02-18 | - | Bokslutskommuniké 2014 |
2014-11-19 | - | Kvartalsrapport 2014-Q3 |
2014-10-13 | - | Extra Bolagsstämma 2014 |
2014-08-20 | - | Kvartalsrapport 2014-Q2 |
2014-04-14 | - | Kvartalsrapport 2014-Q1 |
2014-04-03 | - | Split GUARD 1:5 |
2014-03-26 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
2014-03-25 | - | Årsstämma |
2014-02-21 | - | Bokslutskommuniké 2013 |
2013-11-12 | - | Kvartalsrapport 2013-Q3 |
2013-08-15 | - | Kvartalsrapport 2013-Q2 |
2013-05-22 | - | Årsstämma |
2013-05-15 | - | Kvartalsrapport 2013-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC-035 (ROSgard) in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC-035 has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of 2023.
Guard Therapeutics' investigational drug RMC-035 has in preclinical studies demonstrated favorable treatment effects in several models of acute kidney injury, for example linked to oxygen deficiency (so-called ischemia-reperfusion injuries). The efficacy of RMC-035 is already being evaluated in a comprehensive global Phase 2 study (AKITA) to demonstrate its ability to prevent and treat acute kidney injury in patients undergoing open heart surgery.
The current Phase 1b study of RMC-035 is open-label, without control group, and will include 8–12 patients undergoing kidney transplantation at Karolinska University Hospital in Huddinge. Initially, eight patients will be enrolled in two sequential dose groups, after which an interim analysis of the pharmacokinetic properties of RMC-035 will be conducted. Based on the outcome of this analysis, a potential third dose group may be evaluated. The primary endpoint of the study includes key pharmacokinetic properties of RMC-035, and the results will inform on the design of a potential subsequent Phase 2 study aimed at improving renal function in kidney transplant recipients.
"The Phase 1b study marks the start of an expansion of the clinical development program for RMC-035 to another area with a high need for novel and improved therapies. Based on the mechanism of action of our investigational drug, we see significant opportunities to counteract specific kidney injuries that occur in relation to kidney transplantation and that often leads to both short-term and long-term medical complications in patients, even after successful transplantation", says Guard Therapeutics CEO, Tobias Agervald.
For further information, please contact:
Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com
About Guard Therapeutics
Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.